Haemonetics (HAE) Shares Outstanding (2009 - 2026)

Haemonetics' Shares Outstanding (Entity) history runs 18 years deep, the most recent figure standing at $45.3 million for Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) fell 6.15% year-over-year to $45.3 million in Q1 2026; TTM through Mar 2026 was $45.3 million, a 6.15% decrease from a year earlier, with the FY2026 full-year figure at $45.3 million, down 6.15% from the prior year.
• Shares Outstanding (Entity) fell to $45.3 million in Q1 2026 per HAE's latest filing, from $46.8 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $51.3 million in Q3 2022 and bottomed at $45.3 million in Q1 2026.
• The 5-year median for Shares Outstanding (Entity) is $50.5 million (2022), against an average of $49.7 million.
• Across the five-year window, Shares Outstanding (Entity) advanced 0.88% in 2024 and dropped 7.21% in 2025, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $50.4 million in 2022, then advanced by 0.68% to $50.8 million in 2023, then retreated by 1.08% to $50.2 million in 2024, then declined by 6.78% to $46.8 million in 2025, then declined by 3.37% to $45.3 million in 2026.
• Per Business Quant, the three latest HAE Shares Outstanding (Entity) figures stand at $45.3 million (Q1 2026), $46.8 million (Q4 2025), and $46.7 million (Q3 2025).